Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| 2023 was an impressive year for Legend |
| As many of you have heard, CARVYKTI received a positive opinion from the Committee for Medicinal Products for Human Use to expand into earlier lines of treatment |
| And if you look at efficacy, physicians continue to believe that CARVYKTI provides best-in-class efficacy with nearly three years PFS in late line |
| As Ying mentioned, we generated approximately $159 million in total net sales for CARVYKTI during the fourth quarter, an increase of 189% year-over-year, driven by the progress we have made with ongoing market launches, expanding market share, and capacity improvements |
| We see this as an emerging area with great opportunities |
| The achievements of our global teams have set us up for great success in 2024 and we're poised to provide more therapy to even more patients around the world |
| So that's quite exciting |
| The increase in our fourth quarter performance versus the third quarter was a result of the ongoing launch of CARVYKTI and share gain from capacity expansion and manufacturing efficiencies |
| So I can't comment on our competition's application, also the data, but we firmly believe that CARVYKTI provides overwhelming benefit in the PFS and also overall survival endpoints here |
| So at this point, I think it's still positioned as best-in-class efficacy with the one-time injection convenience |
| To summarize, our spending remains on track and we continue to maintain a strong balance sheet |
| CARVYKTI is the first CAR-T therapy to receive a positive CHMP opinion in the second-line setting for patients with relapsed and lenalidomide-refractory multiple myeloma |
| We anticipate continued quarter-over-quarter growth throughout 2024 as well |
| The results demonstrated clinically meaningful improvements in health-related quality-of-life measures and reductions in symptoms following treatment with CARVYKTI compared to standard-of-care |
| But I can tell you that, Jess, if you look at last year, we applied for FDA approval for two capacity increases in our site in Raritan, New Jersey, and we did successfully achieve both approval from FDA |
| And then we're also seeing, and this was a bit of a change, which was a positive change for patients is, yes, with -- even within the standard risk population, physicians have said that they see them moving forward with CARVYKTI in standard risk, in second line plus that population as well |
| First, we're excited at the prospect of bringing our lead therapy CARVYKTI to more multiple myeloma patients in Europe |
| To sum up 2023, we closed the year with accomplishments on several fronts |
| I am excited to announce we have the new veteran leader with more than 25 years of experience now overseeing our manufacturing sites |
| That's a good one |
| In an oral presentation, we unveiled the data is showing improvements in patient outcomes as early as second-line treatment in our pivotal Phase 3 CARTITUDE-4 study |
| The increases to our production capacity will help ensure we meet our target of supply in CARVYKTI to 10,000 patients by the end of 2025 |
| So, there we are investing on the key technological innovation to address solid tumor target [indiscernible] and hope to generate bystander cytotoxicity effect and therefore being able to extend the PFS benefit for treatment |
| And that is also why, after looking at all the data, as you see, Kostas, we did receive a very clean label from CHMP recommendation |
| CARVYKTI has proven to be the fastest launched CAR-T therapy |
| Birk has earned the trust and respect of our global manufacturing teams and he's already made a big impact |
| We have increased capacity at our Raritan, New Jersey facility, doubling cell processing capacity since the beginning of 2023 |
| We believe our cash balance of $1.3 billion provides us with financial runway through the end of 2025 |
| The increase in production capacity, enabling us to meet growing patient demand comes in parallel with new data we presented at the American Society of Hematology meeting in December |
| I appreciate it and good luck this week |
| Statement |
|---|
| We had a little mechanical difficulty on our end |
| Net loss for the quarter ended December 31st, 2023 was $144.8 million or a loss of $0.40 per share compared to a net loss of $135.9 million or a loss of $0.41 per share for the same period last year |
| Sorry, guys, I have some WiFi problems and they got alright here |
| I think that has, in terms of market erosion where you've seen it, at least in the research that we're doing, is, you're seeing the market erosion occurring with a BCMA when a bi-specific is used in front of a CAR T therapy as opposed to cilta-cel |
| For the year ended December 31st, 2023, net loss was $518.3 million or a loss of $1.47 per share compared to a net loss of $446.3 million or a loss of $1.40 per share for the year ended December 31st, 2022 |
| It's difficult to conclude that |
| A couple of questions from us |
| Regarding our question on parkinsonism in the earlier lines, as we reported at ASCO, given the risk mitigation strategies we implemented following the six cases reported from CARTITUDE-1, we were able to show that the incidence of parkinsonism was going down from about 6% in CARTITUDE-1 to about 0.5% in CARTITUDE-4 |
| With regard to why you're seeing this kind of delayed parkinsonism, I would say there's a couple of hypotheses out there |
Please consider a small donation if you think this website provides you with relevant information